Executive Summary

Robust biodistribution data is a cornerstone of any successful Advanced Therapy Medicinal Product (ATMP) regulatory submission. For sponsors targeting the European market, designing studies that meet the specific expectations of the EMA is a key step in de-risking the development pathway. This requires a nuanced understanding of vector biology, immunogenicity, and the integration of biodistribution data with broader safety and efficacy endpoints to build a cohesive and compelling submission package.

Designing for EMA Scrutiny

An ATMP’s in vivo fate dictates its safety and efficacy profile. Regulators at the EMA require a clear, quantitative understanding of where a vector distributes, how long it persists, and its potential for expression in non-target tissues. A successful study design moves beyond simple tissue collection to provide a comprehensive biological narrative.

Key design elements for an EMA-compliant program include:

• Scientifically Justified Species Selection: Aligning the animal model with the human clinical context and vector tropism.

• Comprehensive Tissue Collection: Implementing a protocol that covers all relevant organs and tissues, with particular attention to gonads for germline transmission assessment.

• Validated Bioanalytical Methods: Using sensitive qPCR or ddPCR assays to provide reliable vector copy number data.

• Extended Time Points: Incorporating long-term tissue analysis to characterize vector clearance or persistence over time.

Mitigating Immunogenicity Risks in Preclinical Models

The presence of preexisting neutralizing antibodies to viral vectors like AAV can significantly impact transduction efficiency and alter biodistribution outcomes. As demonstrated in preclinical research, NAb presence can block vector activity, rendering the resulting data uninterpretable for assessing human risk (PMID: 26067568). Proactively screening large animal models for NAbs is a key risk-mitigation strategy that ensures the selection of naive subjects, strengthening the integrity of the data submitted to the EMA. Through our strategic partners specializing in large animal models, we secure properly characterized cohorts for these pivotal studies.

Integrating Biodistribution into the Complete Data Package

Biodistribution data does not exist in a vacuum. Its value is maximized when correlated with Histology and efficacy readouts. A well-designed program demonstrates that vector distribution to target tissues results in the intended therapeutic effect, while its presence in non-target tissues does not lead to adverse findings. This integrated approach, which connects vector location to biological consequence, provides a powerful and coherent argument for a favorable safety profile (PMID: 35333110).

This rigorous, integrated strategy underpins our development programs, which average an 18-24 month IND timeline. Since 2019, programs managed by our scientific leadership have achieved a 100% IND success rate, a track record we continue at Franklin Biolabs following our 2024 brand launch. All studies are conducted in our >100,000 sq ft GxP-compliant facility, ensuring data integrity for global regulatory submissions.